Letters: Correction about patent expiry for anti-malarial

In a recent update (GP, 15 May) it was stated that the patent for Malarone (combination atovaquone plus proguanil) expired in April 2009.

The patent for atovaquone monotherapy expired in April 2009 but that for Malarone does not expire until November 2013.

We feel that it is important to differentiate Malarone from atovaquone, so that the anti-malarial advice provided by your readers to travellers is as up-to-date and accurate as possible.

Pim Kon, GSK medical director, Uxbridge, south London

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus